NO300968B1 - Vann-uopplöselige joderte estere - Google Patents
Vann-uopplöselige joderte estere Download PDFInfo
- Publication number
- NO300968B1 NO300968B1 NO912671A NO912671A NO300968B1 NO 300968 B1 NO300968 B1 NO 300968B1 NO 912671 A NO912671 A NO 912671A NO 912671 A NO912671 A NO 912671A NO 300968 B1 NO300968 B1 NO 300968B1
- Authority
- NO
- Norway
- Prior art keywords
- group
- substituted
- mmol
- solution
- groups
- Prior art date
Links
- 150000002148 esters Chemical class 0.000 title claims abstract description 9
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 7
- 125000003118 aryl group Chemical group 0.000 claims abstract description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 4
- 210000001124 body fluid Anatomy 0.000 claims abstract description 3
- 239000010839 body fluid Substances 0.000 claims abstract description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 3
- 239000001257 hydrogen Substances 0.000 claims abstract description 3
- 239000002245 particle Substances 0.000 claims description 39
- 150000001875 compounds Chemical class 0.000 claims description 26
- 239000002872 contrast media Substances 0.000 claims description 22
- -1 compound 1-(ethyloxycarbonyloxy)ethyl 3-(alpha-(3-(N-acetyl-N-methylamino)-5-(methylaminocarbonyl)-2,4, 6-triiodo-benzoylamino)-acetylamino)-5-(N-(2-hydroxyethyl)amino-carbonyl)-2,4,6-triiodobenzenecarboxylate Chemical class 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 239000007924 injection Substances 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 125000005118 N-alkylcarbamoyl group Chemical group 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 3
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 36
- 210000004185 liver Anatomy 0.000 abstract description 24
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract description 16
- 229910052740 iodine Inorganic materials 0.000 abstract description 14
- 210000000952 spleen Anatomy 0.000 abstract description 8
- 238000003384 imaging method Methods 0.000 abstract description 7
- 125000002947 alkylene group Chemical group 0.000 abstract description 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 2
- 238000012285 ultrasound imaging Methods 0.000 abstract description 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 74
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 38
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 36
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 34
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 33
- 238000003756 stirring Methods 0.000 description 27
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 22
- 239000002904 solvent Substances 0.000 description 21
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 20
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 18
- 235000019341 magnesium sulphate Nutrition 0.000 description 18
- 238000005160 1H NMR spectroscopy Methods 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- 239000011630 iodine Substances 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 108091006905 Human Serum Albumin Proteins 0.000 description 12
- 102000008100 Human Serum Albumin Human genes 0.000 description 12
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 12
- XRTSXRHJUCUUKL-UHFFFAOYSA-M potassium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate Chemical compound [K+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I XRTSXRHJUCUUKL-UHFFFAOYSA-M 0.000 description 12
- 238000001035 drying Methods 0.000 description 11
- 235000009518 sodium iodide Nutrition 0.000 description 11
- 101100167062 Caenorhabditis elegans chch-3 gene Proteins 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 239000011859 microparticle Substances 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- YVRGKFXJZCTTRB-UHFFFAOYSA-N 1-chloroethyl ethyl carbonate Chemical compound CCOC(=O)OC(C)Cl YVRGKFXJZCTTRB-UHFFFAOYSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- GGGDNPWHMNJRFN-UHFFFAOYSA-N metrizoic acid Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I GGGDNPWHMNJRFN-UHFFFAOYSA-N 0.000 description 5
- 238000000386 microscopy Methods 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 4
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 4
- 125000004494 ethyl ester group Chemical group 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- JYQQWQJCEUMXQZ-UHFFFAOYSA-N methyl cyanate Chemical compound COC#N JYQQWQJCEUMXQZ-UHFFFAOYSA-N 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 229960001025 iohexol Drugs 0.000 description 3
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- RKKWUFKHFYSREM-UHFFFAOYSA-N (1-chloro-3-phenylpropyl) phenyl carbonate Chemical compound C=1C=CC=CC=1OC(=O)OC(Cl)CCC1=CC=CC=C1 RKKWUFKHFYSREM-UHFFFAOYSA-N 0.000 description 2
- DKIFYJOCINOEGZ-UHFFFAOYSA-N (1-phenoxycarbonyloxy-3-phenylpropyl) 3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)OC(CCC=2C=CC=CC=2)OC(=O)OC=2C=CC=CC=2)=C1I DKIFYJOCINOEGZ-UHFFFAOYSA-N 0.000 description 2
- 125000001478 1-chloroethyl group Chemical group [H]C([H])([H])C([H])(Cl)* 0.000 description 2
- YQDLLPYWECJXLT-UHFFFAOYSA-N 1-chloroethyl hexyl carbonate Chemical compound CCCCCCOC(=O)OC(C)Cl YQDLLPYWECJXLT-UHFFFAOYSA-N 0.000 description 2
- UQOZCARFDQXXAM-UHFFFAOYSA-N 1-chloropentyl phenyl carbonate Chemical compound CCCCC(Cl)OC(=O)OC1=CC=CC=C1 UQOZCARFDQXXAM-UHFFFAOYSA-N 0.000 description 2
- HHHKGKFRXJWZJY-UHFFFAOYSA-N 1-hexoxycarbonyloxyethyl 3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate Chemical compound CCCCCCOC(=O)OC(C)OC(=O)C1=C(I)C(NC(C)=O)=C(I)C(N(C)C(C)=O)=C1I HHHKGKFRXJWZJY-UHFFFAOYSA-N 0.000 description 2
- UFGWHYZEQFTPQV-UHFFFAOYSA-N 1-phenoxycarbonyloxypentyl 3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate Chemical compound IC=1C(NC(C)=O)=C(I)C(N(C)C(C)=O)=C(I)C=1C(=O)OC(CCCC)OC(=O)OC1=CC=CC=C1 UFGWHYZEQFTPQV-UHFFFAOYSA-N 0.000 description 2
- YGCZTXZTJXYWCO-UHFFFAOYSA-N 3-phenylpropanal Chemical compound O=CCCC1=CC=CC=C1 YGCZTXZTJXYWCO-UHFFFAOYSA-N 0.000 description 2
- ZBDWOQNPECIPPI-UHFFFAOYSA-N C(C)(=O)NC=1C(=C(C(=C(C=1I)C(=O)OCC)I)N(C(C)=O)C)I Chemical compound C(C)(=O)NC=1C(=C(C(=C(C=1I)C(=O)OCC)I)N(C(C)=O)C)I ZBDWOQNPECIPPI-UHFFFAOYSA-N 0.000 description 2
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- UCSVAARRMAMTIF-UHFFFAOYSA-N chloromethyl phenyl carbonate Chemical compound ClCOC(=O)OC1=CC=CC=C1 UCSVAARRMAMTIF-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N pentanal Chemical compound CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000010491 poppyseed oil Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- REHLJPDVJXFLIO-UHFFFAOYSA-N (2-oxo-1,3-dioxolan-4-yl) 3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)OC2OC(=O)OC2)=C1I REHLJPDVJXFLIO-UHFFFAOYSA-N 0.000 description 1
- WLWSSFQTTXBPKP-UHFFFAOYSA-N 1-(2-methoxyethoxycarbonyloxy)ethyl 3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate Chemical compound COCCOC(=O)OC(C)OC(=O)C1=C(I)C(NC(C)=O)=C(I)C(N(C)C(C)=O)=C1I WLWSSFQTTXBPKP-UHFFFAOYSA-N 0.000 description 1
- RLCSVIMOWLKELL-UHFFFAOYSA-N 1-chloroethyl phenyl carbonate Chemical compound CC(Cl)OC(=O)OC1=CC=CC=C1 RLCSVIMOWLKELL-UHFFFAOYSA-N 0.000 description 1
- RRPXADPTOYPAMJ-UHFFFAOYSA-N 1-ethoxycarbonyloxyethyl 3,5-diacetamido-2,4,6-triiodobenzoate Chemical compound CCOC(=O)OC(C)OC(=O)C1=C(I)C(NC(C)=O)=C(I)C(NC(C)=O)=C1I RRPXADPTOYPAMJ-UHFFFAOYSA-N 0.000 description 1
- VGUMKYNTZLRUPX-UHFFFAOYSA-N 1-ethoxycarbonyloxyethyl 3-acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoate Chemical compound CCOC(=O)OC(C)OC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)NC)=C1I VGUMKYNTZLRUPX-UHFFFAOYSA-N 0.000 description 1
- VVAMMSNSZXELJH-UHFFFAOYSA-N 1-ethoxycarbonyloxyethyl 3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate Chemical compound CCOC(=O)OC(C)OC(=O)C1=C(I)C(NC(C)=O)=C(I)C(N(C)C(C)=O)=C1I VVAMMSNSZXELJH-UHFFFAOYSA-N 0.000 description 1
- CSWZOWPFIWVZTN-UHFFFAOYSA-N 1-phenoxycarbonyloxyethyl 3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate Chemical compound IC=1C(NC(C)=O)=C(I)C(N(C)C(C)=O)=C(I)C=1C(=O)OC(C)OC(=O)OC1=CC=CC=C1 CSWZOWPFIWVZTN-UHFFFAOYSA-N 0.000 description 1
- SGMRVPXGKYCCDH-UHFFFAOYSA-N 1-phenylmethoxycarbonyloxyethyl 3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate Chemical compound IC=1C(NC(C)=O)=C(I)C(N(C)C(C)=O)=C(I)C=1C(=O)OC(C)OC(=O)OCC1=CC=CC=C1 SGMRVPXGKYCCDH-UHFFFAOYSA-N 0.000 description 1
- ZMZGFLUUZLELNE-UHFFFAOYSA-N 2,3,5-triiodobenzoic acid Chemical class OC(=O)C1=CC(I)=CC(I)=C1I ZMZGFLUUZLELNE-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- RQANNJNNJBTXKB-UHFFFAOYSA-N 2-[[2-[3,5-bis[(2,2-dimethyl-1,3-dioxolan-4-yl)-methylcarbamoyl]-2,4,6-triiodophenyl]acetyl]amino]ethyl 1-chloroethyl carbonate Chemical compound IC=1C(C(=O)N(C)C2OC(C)(C)OC2)=C(I)C(CC(=O)NCCOC(=O)OC(Cl)C)=C(I)C=1C(=O)N(C)C1COC(C)(C)O1 RQANNJNNJBTXKB-UHFFFAOYSA-N 0.000 description 1
- DOWILIDAHIVNKG-UHFFFAOYSA-N 2-[n-acetyl-3,5-bis[(2,2-dimethyl-1,3-dioxolan-4-yl)-methylcarbamoyl]-2,4,6-triiodoanilino]ethyl 1-chloroethyl carbonate Chemical compound IC=1C(C(=O)N(C)C2OC(C)(C)OC2)=C(I)C(N(C(C)=O)CCOC(=O)OC(Cl)C)=C(I)C=1C(=O)N(C)C1COC(C)(C)O1 DOWILIDAHIVNKG-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- OYOKPDLAMOMTEE-UHFFFAOYSA-N 4-chloro-1,3-dioxolan-2-one Chemical compound ClC1COC(=O)O1 OYOKPDLAMOMTEE-UHFFFAOYSA-N 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- VQJPGLLQWGMDJX-UHFFFAOYSA-N 5-[acetyl(2-hydroxyethyl)amino]-1-n,3-n-bis[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-2,4,6-triiodobenzene-1,3-dicarboxamide Chemical compound IC=1C(C(=O)NCC2OC(C)(C)OC2)=C(I)C(N(CCO)C(=O)C)=C(I)C=1C(=O)NCC1COC(C)(C)O1 VQJPGLLQWGMDJX-UHFFFAOYSA-N 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- ZBJJDYGJCNTNTH-UHFFFAOYSA-N Betahistine mesilate Chemical group CS(O)(=O)=O.CS(O)(=O)=O.CNCCC1=CC=CC=N1 ZBJJDYGJCNTNTH-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- PZOPFNQUACDVKU-UHFFFAOYSA-N [chloro(phenyl)methyl] phenyl carbonate Chemical compound C=1C=CC=CC=1C(Cl)OC(=O)OC1=CC=CC=C1 PZOPFNQUACDVKU-UHFFFAOYSA-N 0.000 description 1
- KFYRSOCQGPNMOP-UHFFFAOYSA-N [phenoxycarbonyloxy(phenyl)methyl] 3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)OC(OC(=O)OC=2C=CC=CC=2)C=2C=CC=CC=2)=C1I KFYRSOCQGPNMOP-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 1
- FFINMCNLQNTKLU-UHFFFAOYSA-N adipiodone Chemical compound OC(=O)C1=C(I)C=C(I)C(NC(=O)CCCCC(=O)NC=2C(=C(C(O)=O)C(I)=CC=2I)I)=C1I FFINMCNLQNTKLU-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- ZRWKDMLCIQLGSK-UHFFFAOYSA-N benzyl 1-chloroethyl carbonate Chemical compound CC(Cl)OC(=O)OCC1=CC=CC=C1 ZRWKDMLCIQLGSK-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- YJTAFVPEDKYYLZ-UHFFFAOYSA-N carbonic acid;3-chloro-1-methoxybutane Chemical compound OC(O)=O.COCCC(C)Cl YJTAFVPEDKYYLZ-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960005223 diatrizoic acid Drugs 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000005191 hydroxyalkylamino group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229940029355 iodipamide Drugs 0.000 description 1
- 229960004647 iopamidol Drugs 0.000 description 1
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 description 1
- 229960000824 iopentol Drugs 0.000 description 1
- IUNJANQVIJDFTQ-UHFFFAOYSA-N iopentol Chemical compound COCC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I IUNJANQVIJDFTQ-UHFFFAOYSA-N 0.000 description 1
- 229960002603 iopromide Drugs 0.000 description 1
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000005905 mesyloxy group Chemical group 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960000554 metrizamide Drugs 0.000 description 1
- 229960004712 metrizoic acid Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- YQISJSIEHKGSLM-UHFFFAOYSA-N phenoxycarbonyloxymethyl 3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)OCOC(=O)OC=2C=CC=CC=2)=C1I YQISJSIEHKGSLM-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- FHSMUBSUZOMNIN-UHFFFAOYSA-M potassium;3,5-diacetamido-2,4,6-triiodobenzoate Chemical compound [K+].CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I FHSMUBSUZOMNIN-UHFFFAOYSA-M 0.000 description 1
- MNGSONQLOCMNHF-UHFFFAOYSA-M potassium;3-acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoate Chemical compound [K+].CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MNGSONQLOCMNHF-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- ZPHGMBGIFODUMF-UHFFFAOYSA-N thiophen-2-ylmethanol Chemical compound OCC1=CC=CS1 ZPHGMBGIFODUMF-UHFFFAOYSA-N 0.000 description 1
- ZCUFMDLYAMJYST-UHFFFAOYSA-N thorium dioxide Chemical compound O=[Th]=O ZCUFMDLYAMJYST-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having carbon atoms of carboxamide groups, amino groups and at least three atoms of bromine or iodine, bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0476—Particles, beads, capsules, spheres
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/88—Carboxylic acid amides having nitrogen atoms of carboxamide groups bound to an acyclic carbon atom and to a carbon atom of a six-membered aromatic ring wherein at least one ortho-hydrogen atom has been replaced
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D317/34—Oxygen atoms
- C07D317/36—Alkylene carbonates; Substituted alkylene carbonates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/32—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Silicates, Zeolites, And Molecular Sieves (AREA)
- Silicon Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB898900376A GB8900376D0 (en) | 1989-01-09 | 1989-01-09 | Iodinated esters |
| PCT/EP1990/000053 WO1990007491A1 (en) | 1989-01-09 | 1990-01-08 | Iodinated esters |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO912671L NO912671L (no) | 1991-07-08 |
| NO912671D0 NO912671D0 (no) | 1991-07-08 |
| NO300968B1 true NO300968B1 (no) | 1997-08-25 |
Family
ID=10649773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO912671A NO300968B1 (no) | 1989-01-09 | 1991-07-08 | Vann-uopplöselige joderte estere |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US5370861A (de) |
| EP (1) | EP0452377B1 (de) |
| JP (1) | JP2703111B2 (de) |
| AT (1) | ATE111889T1 (de) |
| AU (1) | AU631837B2 (de) |
| CA (1) | CA2045543C (de) |
| DE (1) | DE69012796T2 (de) |
| DK (1) | DK0452377T3 (de) |
| ES (1) | ES2060138T3 (de) |
| FI (1) | FI912664A0 (de) |
| GB (1) | GB8900376D0 (de) |
| HU (1) | HU214328B (de) |
| IE (1) | IE64500B1 (de) |
| NO (1) | NO300968B1 (de) |
| NZ (1) | NZ232050A (de) |
| RU (1) | RU2088579C1 (de) |
| WO (1) | WO1990007491A1 (de) |
| ZA (1) | ZA90143B (de) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8900376D0 (en) * | 1989-01-09 | 1989-03-08 | Nycomed As | Iodinated esters |
| AU642066B2 (en) * | 1991-01-25 | 1993-10-07 | Nanosystems L.L.C. | X-ray contrast compositions useful in medical imaging |
| SE470086B (sv) * | 1991-04-23 | 1993-11-08 | Kabi Pharmacia Ab | Organspecifik emulsion |
| US5607661A (en) * | 1991-07-05 | 1997-03-04 | Nycomed Imaging As | Aggregates of x-ray microparticles for ultrasound imaging |
| DK0605477T4 (da) * | 1991-09-17 | 2007-10-01 | Ge Healthcare As | Gasformige ultralydskontrastmidler |
| US5409688A (en) * | 1991-09-17 | 1995-04-25 | Sonus Pharmaceuticals, Inc. | Gaseous ultrasound contrast media |
| MX9205298A (es) * | 1991-09-17 | 1993-05-01 | Steven Carl Quay | Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido |
| US5674468A (en) * | 1992-03-06 | 1997-10-07 | Nycomed Imaging As | Contrast agents comprising gas-containing or gas-generating polymer microparticles or microballoons |
| GB9221329D0 (en) * | 1992-10-10 | 1992-11-25 | Delta Biotechnology Ltd | Preparation of further diagnostic agents |
| US5330739A (en) * | 1992-12-04 | 1994-07-19 | Sterling Winthrop Inc. | Iodinated benzoyl acetals and ketals for x-ray imaging |
| NZ250063A (en) * | 1992-12-14 | 1996-03-26 | Eastman Kodak Co | Iodinated aromatic acid ester derivatives; x-ray contrast compositions |
| US5322679A (en) * | 1992-12-16 | 1994-06-21 | Sterling Winthrop Inc. | Iodinated aroyloxy esters |
| IL108416A (en) | 1993-01-25 | 1998-10-30 | Sonus Pharma Inc | Colloids with phase difference as contrast ultrasound agents |
| PL176116B1 (pl) * | 1993-01-25 | 1999-04-30 | Sonus Pharma Inc | Środek kontrastowy do ultrasonografii i sposób wytwarzania środka kontrastowego do ultrasonografii |
| US5558855A (en) * | 1993-01-25 | 1996-09-24 | Sonus Pharmaceuticals | Phase shift colloids as ultrasound contrast agents |
| NO940115D0 (no) * | 1994-01-13 | 1994-01-13 | Nycomed Imaging As | Kontrastmidler for roentgen- og magnettomografisk avbildning |
| US5686061A (en) * | 1994-04-11 | 1997-11-11 | The Board Of Regents Of The University Of Texas System | Particulate contrast media derived from non-ionic water soluble contrast agents for CT enhancement of hepatic tumors |
| GB9423419D0 (en) * | 1994-11-19 | 1995-01-11 | Andaris Ltd | Preparation of hollow microcapsules |
| IT1271134B (it) * | 1994-12-01 | 1997-05-26 | Bracco Spa | Derivati iodurati del bifenile e loro impiego diagnostico |
| US5543133A (en) * | 1995-02-14 | 1996-08-06 | Nanosystems L.L.C. | Process of preparing x-ray contrast compositions containing nanoparticles |
| DE19622283A1 (de) * | 1996-05-23 | 1997-11-27 | Schering Ag | Verfahren zur terminalen Sterilisierung von befüllten Spritzen |
| US6017310A (en) * | 1996-09-07 | 2000-01-25 | Andaris Limited | Use of hollow microcapsules |
| US5925683A (en) * | 1996-10-17 | 1999-07-20 | Target Therapeutics, Inc. | Liquid embolic agents |
| US6068600A (en) * | 1996-12-06 | 2000-05-30 | Quadrant Healthcare (Uk) Limited | Use of hollow microcapsules |
| FR2784580B1 (fr) * | 1998-10-16 | 2004-06-25 | Biosepra Inc | Microspheres de polyvinyl-alcool et procedes de fabrication de celles-ci |
| WO2001066016A1 (en) * | 2000-03-06 | 2001-09-13 | Scimed Life Systems, Inc. | Embolic agents visible under ultrasound |
| WO2002060975A1 (en) | 2001-01-31 | 2002-08-08 | The Procter & Gamble Company | Synthesis of polyol medium fatty acid polyesters |
| US7462366B2 (en) | 2002-03-29 | 2008-12-09 | Boston Scientific Scimed, Inc. | Drug delivery particle |
| AU2003240000A1 (en) | 2002-06-12 | 2003-12-31 | Boston Scientific Limited | Bulking agents |
| US7842377B2 (en) | 2003-08-08 | 2010-11-30 | Boston Scientific Scimed, Inc. | Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient |
| US8012454B2 (en) | 2002-08-30 | 2011-09-06 | Boston Scientific Scimed, Inc. | Embolization |
| US7883490B2 (en) | 2002-10-23 | 2011-02-08 | Boston Scientific Scimed, Inc. | Mixing and delivery of therapeutic compositions |
| US7976823B2 (en) | 2003-08-29 | 2011-07-12 | Boston Scientific Scimed, Inc. | Ferromagnetic particles and methods |
| US7736671B2 (en) | 2004-03-02 | 2010-06-15 | Boston Scientific Scimed, Inc. | Embolization |
| US8173176B2 (en) | 2004-03-30 | 2012-05-08 | Boston Scientific Scimed, Inc. | Embolization |
| US7311861B2 (en) | 2004-06-01 | 2007-12-25 | Boston Scientific Scimed, Inc. | Embolization |
| US8012457B2 (en) | 2004-06-04 | 2011-09-06 | Acusphere, Inc. | Ultrasound contrast agent dosage formulation |
| US8425550B2 (en) | 2004-12-01 | 2013-04-23 | Boston Scientific Scimed, Inc. | Embolic coils |
| US7858183B2 (en) | 2005-03-02 | 2010-12-28 | Boston Scientific Scimed, Inc. | Particles |
| US7727555B2 (en) | 2005-03-02 | 2010-06-01 | Boston Scientific Scimed, Inc. | Particles |
| US7963287B2 (en) | 2005-04-28 | 2011-06-21 | Boston Scientific Scimed, Inc. | Tissue-treatment methods |
| US9463426B2 (en) | 2005-06-24 | 2016-10-11 | Boston Scientific Scimed, Inc. | Methods and systems for coating particles |
| US8007509B2 (en) | 2005-10-12 | 2011-08-30 | Boston Scientific Scimed, Inc. | Coil assemblies, components and methods |
| US8152839B2 (en) | 2005-12-19 | 2012-04-10 | Boston Scientific Scimed, Inc. | Embolic coils |
| US8101197B2 (en) | 2005-12-19 | 2012-01-24 | Stryker Corporation | Forming coils |
| US7947368B2 (en) | 2005-12-21 | 2011-05-24 | Boston Scientific Scimed, Inc. | Block copolymer particles |
| US8414927B2 (en) | 2006-11-03 | 2013-04-09 | Boston Scientific Scimed, Inc. | Cross-linked polymer particles |
| WO2012080279A1 (en) | 2010-12-17 | 2012-06-21 | Universite De Strasbourg | Radiopaque iodinated products intended for use medical imaging and their methods of preparation |
| WO2013121284A1 (en) | 2012-02-14 | 2013-08-22 | Universite De Strasbourg | Iodinated products intended for a use for the medical imaging and their methods of preparation |
| JP6124273B2 (ja) * | 2012-02-29 | 2017-05-10 | 国立大学法人金沢大学 | 分子イメージングにより代謝機能を測定するための検査薬 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL239757A (de) * | 1958-06-03 | |||
| GB1363847A (en) * | 1970-09-09 | 1974-08-21 | Beecham Group Ltd | Iodinated organic acid derivatives for use as x-ray contrast agents |
| US4018783A (en) * | 1970-09-09 | 1977-04-19 | Beecham Group Limited | Esters of metrizoic acid |
| LU80207A1 (de) * | 1978-09-07 | 1980-04-21 | H Kalbacher | Neue substituierte kohlensaeureester und urethane,verfahren zu ihrer herstellung und deren verwendung |
| GB2157283B (en) * | 1984-03-30 | 1987-07-08 | Squibb & Sons Inc | Esters of 3,5-diacetylamino-2,4,6-triiodobenzoic acid as x-ray contrast agents |
| GB8900376D0 (en) * | 1989-01-09 | 1989-03-08 | Nycomed As | Iodinated esters |
-
1989
- 1989-01-09 GB GB898900376A patent/GB8900376D0/en active Pending
-
1990
- 1990-01-08 US US08/210,739 patent/US5370861A/en not_active Expired - Fee Related
- 1990-01-08 AU AU48142/90A patent/AU631837B2/en not_active Ceased
- 1990-01-08 HU HU901091A patent/HU214328B/hu not_active IP Right Cessation
- 1990-01-08 AT AT90901583T patent/ATE111889T1/de active
- 1990-01-08 IE IE6590A patent/IE64500B1/en not_active IP Right Cessation
- 1990-01-08 JP JP2501483A patent/JP2703111B2/ja not_active Expired - Fee Related
- 1990-01-08 RU SU905001111A patent/RU2088579C1/ru active
- 1990-01-08 DK DK90901583.6T patent/DK0452377T3/da active
- 1990-01-08 DE DE69012796T patent/DE69012796T2/de not_active Expired - Fee Related
- 1990-01-08 CA CA002045543A patent/CA2045543C/en not_active Expired - Fee Related
- 1990-01-08 ES ES90901583T patent/ES2060138T3/es not_active Expired - Lifetime
- 1990-01-08 WO PCT/EP1990/000053 patent/WO1990007491A1/en active IP Right Grant
- 1990-01-08 EP EP90901583A patent/EP0452377B1/de not_active Expired - Lifetime
- 1990-01-08 NZ NZ232050A patent/NZ232050A/en unknown
- 1990-01-09 ZA ZA90143A patent/ZA90143B/xx unknown
-
1991
- 1991-06-03 FI FI912664A patent/FI912664A0/fi unknown
- 1991-07-08 NO NO912671A patent/NO300968B1/no not_active IP Right Cessation
-
1994
- 1994-09-30 US US08/315,502 patent/US5416223A/en not_active Expired - Fee Related
-
1995
- 1995-05-12 US US08/440,456 patent/US5559266A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US5370861A (en) | 1994-12-06 |
| JP2703111B2 (ja) | 1998-01-26 |
| RU2088579C1 (ru) | 1997-08-27 |
| CA2045543C (en) | 2000-03-14 |
| AU4814290A (en) | 1990-08-01 |
| NO912671L (no) | 1991-07-08 |
| WO1990007491A1 (en) | 1990-07-12 |
| EP0452377A1 (de) | 1991-10-23 |
| DK0452377T3 (da) | 1994-10-17 |
| ES2060138T3 (es) | 1994-11-16 |
| GB8900376D0 (en) | 1989-03-08 |
| JPH04502617A (ja) | 1992-05-14 |
| ATE111889T1 (de) | 1994-10-15 |
| DE69012796T2 (de) | 1995-02-02 |
| IE64500B1 (en) | 1995-08-09 |
| HU214328B (hu) | 1998-03-02 |
| FI912664A0 (fi) | 1991-06-03 |
| NZ232050A (en) | 1991-07-26 |
| NO912671D0 (no) | 1991-07-08 |
| DE69012796D1 (de) | 1994-10-27 |
| US5559266A (en) | 1996-09-24 |
| IE900065L (en) | 1990-07-09 |
| CA2045543A1 (en) | 1990-07-10 |
| AU631837B2 (en) | 1992-12-10 |
| EP0452377B1 (de) | 1994-09-21 |
| HUT57700A (en) | 1991-12-30 |
| US5416223A (en) | 1995-05-16 |
| ZA90143B (en) | 1990-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO300968B1 (no) | Vann-uopplöselige joderte estere | |
| US5354549A (en) | Iodinated esters | |
| US8124806B2 (en) | Contrast agents | |
| EP2200656B1 (de) | Kontrastmittel | |
| AU614310B2 (en) | New substituted dicarboxylic acid-bis(3,5-dicarbamoyl- 2,4,6-triiodoanilides), process for their production as well as X-ray contrast media containing them | |
| EP0300828B1 (de) | Jodierte Ester | |
| US4395391A (en) | Unsymmetrically substituted dicarboxylic-acid-bis-(2,4,6-triiodo-anilides), their preparation, and x-ray contrast media containing same | |
| WO2009047317A1 (en) | Contrast agents | |
| US4175544A (en) | Iodo-aryl carbonates for use in methods in radiography | |
| WO2009005364A1 (en) | Contrast agents | |
| WO2008123779A1 (en) | Trisubstituted triazamacrocycli c compounds and their use as contrast agents | |
| EP2200655B1 (de) | Kontrastmittel | |
| WO2009005365A1 (en) | Contrast agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |
Free format text: LAPSED IN JULY 2002 |